IMMUNE & THYMIC / FAQ
Questions From the Literature
Direct, citation-anchored answers to the questions readers most often bring to these three immune and thymic peptides.
What is Thymosin Alpha-1?
Thymosin Alpha-1 is a 28-amino-acid, N-terminally acetylated thymic polypeptide. It was first isolated from calf thymus fraction 5 in 1977 by Goldstein and colleagues, who determined its complete sequence [7]. In the body it is derived from a larger precursor called prothymosin alpha; the synthetic version, thymalfasin, is sequence-identical and is approved as a drug in more than 35 countries [2]. It is distinct from Thymulin (a zinc-dependent 9-amino-acid hormone) and from thymosin beta-4 / TB-500 (an actin-binding peptide from a completely different protein family).
What does Thymosin Alpha-1 do?
At the mechanistic level, Thymosin Alpha-1 operates at the innate-adaptive immune interface. It signals through Toll-like receptors — particularly TLR2 and TLR9 — on dendritic cells and monocytes, promoting their maturation and interleukin-12 production, which in turn drives T-cell differentiation toward a Th1 (effector) profile. In parallel, it activates the IDO/tryptophan-catabolism pathway to generate regulatory T cells and interleukin-10, providing a counterbalancing tolerogenic signal [6]. In practice — in animals and in clinical settings — this dual profile has been studied for restoring immune function in states of depletion: chronic viral hepatitis, sepsis-related immunosuppression, and cancer-related T-cell exhaustion [3][4].
What is Thymosin Alpha-1 used for in research?
The research and clinical-use base spans several areas. In chronic viral hepatitis (both B and C), thymalfasin is an approved treatment in multiple countries based on its immune-stimulatory properties [2]. In sepsis, it has been studied in two large controlled trials — ETASS (marginal positive signal at conventional significance) [5] and TESTS (null result in 1,106 patients) [1]. In oncology, it is explored as an immunostimulatory adjuvant alongside chemotherapy and checkpoint inhibitors in melanoma, hepatocellular carcinoma, and lung cancer [4]. A retrospective COVID-19 cohort found it associated with reversal of T-cell exhaustion and lower mortality in severe cases [3].
Is Thymosin Alpha-1 FDA-approved?
No. Thymosin Alpha-1 (thymalfasin) is not FDA-approved for marketing in the United States. It is approved as a drug in more than 35 other countries for indications including chronic hepatitis B and C and adjunctive immunomodulation in cancer [2]. In the US, use is limited to investigational settings and compounding; it is not available as a marketed pharmaceutical. Research-grade material sold as a research chemical falls outside the regulated drug-quality chain [2].
What is Thymulin?
Thymulin is a nine-amino-acid thymic hormone (sequence: pyroGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) produced exclusively by thymic epithelial cells. It was historically called serum thymic factor (FTS). Its defining property is absolute zinc-dependence: the peptide is biologically inert without zinc and becomes active only when bound to one zinc(II) ion in a 1:1 ratio [12]. It drives T-lymphocyte differentiation and participates in a bidirectional thymus-neuroendocrine axis, signaling between the thymus and the pituitary [11].
What is Thymulin peptide used for in research?
Thymulin research has followed two main tracks. First, classic immunology: understanding how thymic epithelial cells regulate T-lymphocyte maturation through the zinc-thymulin hormone signal, and how zinc deficiency depresses immune function by lowering thymulin activity [12]. Second, gene therapy: because thymulin production declines with age and thymic involution, researchers have used thymulin-expressing adenoviral and nanoparticle vectors to restore circulating thymulin in athymic animal models [9] and to deliver anti-inflammatory thymulin locally in the lung to reverse established asthma pathology [8].
Is Thymulin the same as serum thymic factor (FTS)?
Yes. Thymulin and serum thymic factor (FTS, from facteur thymique serique) are the same molecule. The FTS designation was used in earlier literature; "thymulin" is the current preferred name. The active form is always the zinc-bound complex (Zn-thymulin or FTS-Zn). The zinc-free apopeptide is biologically inactive and is not detected by the bioassays that measure "thymulin activity" in serum [12].
How is Thymulin different from Thymosin Alpha-1?
They are chemically and mechanistically distinct. Thymulin is a 9-amino-acid zinc-dependent hormone produced only by thymic epithelial cells; it acts as the thymus's own output signal, directly regulating T-cell maturation and communicating with the neuroendocrine system [12][11]. Thymosin Alpha-1 is a 28-amino-acid N-terminally acetylated peptide that acts at the innate-adaptive immune interface, signaling through Toll-like receptors on dendritic cells to orchestrate T-cell polarization and tolerogenic regulation [6]. Different sizes, different sequences, different receptors, different mechanisms. Neither derives from the other.
What is KPV peptide?
KPV is a three-amino-acid peptide — lysine (K), proline (P), valine (V) — corresponding to residues 11-13 of the hormone alpha-MSH. It is also written as alpha-MSH(11-13). Its defining feature is that it retains the parent hormone's anti-inflammatory activity while discarding its melanogenic (pigment-producing) effect [17]. It is a research peptide with no approved drug or dietary-supplement status and no validated human pharmacokinetics.
What does KPV peptide do?
KPV suppresses inflammation primarily by inhibiting NF-kB and MAP-kinase signaling pathways inside cells, reducing pro-inflammatory cytokines including IL-1beta and TNF-alpha [15]. In intestinal epithelial cells it is taken up directly via the PepT1 di/tripeptide transporter, which is upregulated in inflamed tissue — creating a built-in selectivity for active inflammation sites [15]. Its anti-inflammatory effect operates independently of the MC1R melanocortin receptor [16]. Most of its research is in mouse models of gut inflammation.
What is KPV peptide good for, according to the research?
The research signal is strongest for quieting gut inflammation. In mouse DSS-colitis and adoptive-transfer colitis models, KPV reduced inflammatory infiltrate, myeloperoxidase activity, and colonic damage while accelerating recovery [16]. Targeted delivery systems — both hyaluronic-acid nanoparticles [14] and PepT1-targeted nanodrugs [13] — outperformed non-targeted formulations in delivering KPV to inflamed colon tissue. A comprehensive review also documents anti-inflammatory activity across a broader range of models, including skin, eye, airway, and joints [17]. All of this is preclinical; KPV is not an approved treatment for any condition, and this site gives no dosing or medical advice [15].
Are Thymosin Alpha-1, Thymulin, and KPV the same thing as thymosin beta-4 or TB-500?
No. They are completely different molecules from different protein families. Thymosin beta-4 (and its synthetic fragment TB-500) is an actin-binding peptide that promotes cell migration and wound healing; it derives from the beta-thymosin protein family. Thymosin Alpha-1 derives from prothymosin alpha and acts as an immunomodulatory signal through TLR-mediated dendritic-cell activation. Thymulin is a zinc-dependent nonapeptide hormone produced by thymic epithelial cells. KPV is a melanocortin-derived anti-inflammatory tripeptide. The word "thymosin" appears in two of the names by historical convention, but it does not imply chemical or mechanistic similarity. These are distinct molecules with distinct mechanisms.